UlrikeKirstenBuchwaldMD

PubMed

• Phase 3 trial to evaluate the safety, tolerability, and immunogenicity of V114, a 15-valent pneumococcal conjugate vaccine, followed by 23-valent pneumococcal polysacc...
  Laura L Hammitt, Dean Quinn, Ewa Janczewska, Francisco J Pasquel, Richard Tytus, K Rajender Reddy, Katia Abarca, Ilsiyar M Khaertynova, Ron Dagan, Rachel Dawson, Jenni...> ;Human Vaccines & Immunotherapeutics. 2023 Dec 31
• PCV15, a pneumococcal conjugate vaccine, for the prevention of invasive pneumococcal disease in infants and children.
  Chapman, T., Olarte, L., Dbaibo, G., Tamms, G., Lupinacci, R., Feemster, K., Houston, A., Buchwald, U., Banniettis, N.> ;Expert Review of Vaccines. 2023 Dec 20
• Pneumococcal Vaccine Breakthrough and Failure in Infants and Children: A Narrative Review.
  Feemster, K., Weaver, J., Cox, K., McIntosh, E., Spoulou, V., Buchwald, U., Banniettis, N.> ;Vaccines. 2023 Nov 24
• 1 citations
  An indirect treatment comparison (ITC) and matching-adjusted indirect comparison (MAIC) between a 15-valent (V114) and a 20-valent (PCV20) pneumococcal conjugate vacci...
  Shahrul Mt-Isa, Justin R Chumbley, Emma L Crawford, Natalie Banniettis, Ulrike K Buchwald, Jessica Weaver, Thomas Weiss> ;Expert Review of Vaccines. 2023 Oct 19
• 1 citations
  Safety and Immunogenicity of V114 in Preterm Infants: A Pooled Analysis of Four Phase Three Studies.
  Timothy J Chapman, Shrita M Patel, Sheryl A Flores, Shengjie Xu, Robert Lupinacci, Yaru Shi, Tulin Shekar, Kristen Feemster, Jumi Yi, Gretchen Tamms, Janusz Kaminski, ...> ;The Pediatric Infectious Disease Journal. 2023 Nov 1
• 1 citations
  The 15-valent pneumococcal conjugate vaccine V114 induces cross-reactive antibodies against pneumococcal serotype 6C.
  Yaru Shi, Katrina M Nolan, Robert L Burton, Tulin Shekar, Rocio D Murphy, Natalie Banniettis, Luwy Musey, Ulrike K Buchwald> ;Human Vaccines & Immunotherapeutics. 2023 Aug 1
• 1 citations
  A Phase 3, Randomized, Double-Blind, Comparator-Controlled Study to Evaluate Safety, Tolerability, and Immunogenicity of V114, a 15-Valent Pneumococcal Conjugate Vacci...
  Marissa Wilck, Oliver A Cornely, Catherine Cordonnier, Juan Diego Velez, Per Ljungman, Johan Maertens, Dominik Selleslag, Kathleen M Mullane, Samir Nabhan, Qiuxu Chen,...> ;Clinical Infectious Diseases. 2023 Oct 13
• A phase I study of intra-anal artesunate (suppositories) to treat anal high-grade squamous intraepithelial lesions.
  Fang, S., Plesa, M., Cowell, N., Staudt, E., Twaroski, K., Carchman, E., Buchwald, U., Trimble, C.> ;Plos One. 2023 Jan 1
• 1 citations
  Letter to the editor in response to: A systematic review of invasive pneumococcal disease vaccine failures and breakthrough with higher-valency pneumococcal conjugate ...
  Kristen Feemster, Natalie Banniettis, Ulrike K Buchwald> ;Expert Review of Vaccines. 2022 Dec 1
• 7 citations
  Effectiveness, immunogenicity, and safety of the quadrivalent HPV vaccine in women and men aged 27-45 years.
  Ivette Maldonado, Manuel Plata, Mauricio Gonzalez, Alfonso Correa, Claudia Nossa, Anna R Giuliano, Elmar A Joura, Alex Ferenczy, Brigitte M Ronnett, Mark H Stoler, Hao...> ;Human Vaccines & Immunotherapeutics. 2022 Nov 30
• 2 citations
  Safety and Immunogenicity of V114, a 15-valent Pneumococcal Conjugate Vaccine, Compared with 13-valent Pneumococcal Conjugate Vaccine in Japanese Adults Aged ≥65 Years...
  Hiroyuki Kishino, Miyuki Sawata, Rie Igarashi, Masayoshi Shirakawa, Alison Pedley, Luwy Musey, Heather Loryn Platt, Ulrike Kirsten Buchwald> ;Japanese Journal of Infectious Diseases. 2022 Nov 22
• Comment on Chandler et al. 23-Valent Pneumococcal Polysaccharide Vaccination Does Not Prevent Community-Acquired Pneumonia Hospitalizations Due to Vaccine-Type.2022,, ...
  Nicole Cossrow, Rennie Joshi, Kenneth Klinker, Ulrike K Buchwald> ;Microorganisms. 2022 Oct 8
• 1 citations
  Predictors of in-hospital mortality in a cohort of people living with HIV (PLHIV) admitted to an academic medical intensive care unit from 2009 to 2014: A retrospectiv...
  Leonard A Sowah, Nivya George, Michelle Doll, Christine Chiou, Pavan Bhat, Christopher Smith, Danica Palacio, Carl Nieweld, Eric Miller, Ibukunolupo Oni, Christine Okw...> ;Medicine. 2022 Jul 15
• Response to Vyse et al., "A review of current data to support decision making for introduction of next generation higher valency pneumococcal conjugate vaccination of ...
  Rachel Dawson, Ulrike K Buchwald, Kelly D Johnson, Laura Spowart> ;Expert Review of Vaccines. 2022 Jun 1
• 10 citations
  Immunogenicity, Safety, and Tolerability of V114, a 15-Valent Pneumococcal Conjugate Vaccine, in Immunocompetent Adults Aged 18-49 Years With or Without Risk Factors f...
  Laura L Hammitt, Dean Quinn, Ewa Janczewska, Francisco J Pasquel, Richard Tytus, K Rajender Reddy, Katia Abarca, Ilsiyar M Khaertynova, Ron Dagan, Jennifer McCauley, K...> ;Open Forum Infectious Diseases. 2022 Mar 1
• 5 citations
  Lot-to-lot consistency, safety, tolerability, and immunogenicity of V114, a 15-valent pneumococcal conjugate vaccine, in healthy adults aged ≥50 years: A randomized ph...
  Jakub K Simon, Nina Breinholt Staerke, Maria Hemming-Harlo, Stacey Layle, Ron Dagan, Tulin Shekar, Alison Pedley, Patricia Jumes, Gretchen Tamms, Tina Sterling, Luwy M...> ;Vaccine. 2022 Feb 23
• 6 citations
  Safety and immunogenicity of V114, a 15-valent pneumococcal conjugate vaccine, in adults living with HIV: a randomized phase 3 study.
  Lerato Mohapi, Yvett Pinedo, Olayemi Osiyemi, Khuanchai Supparatpinyo, Winai Ratanasuwan, Jean-Michel Molina, Ron Dagan, Gretchen M. Tamms, Tina M. Sterling, Ying Zhan...> ;AIDS. 2021 Nov 22
• 22 citations
  The pipeline of new molecules and regimens against drug-resistant tuberculosis.
  Todd A. Black, Ulrike K. Buchwald> ;Journal of Clinical Tuberculosis and Other Mycobacterial Diseases. 2021 Nov 5
• 10 citations
  Safety, tolerability, and immunogenicity of V114, a 15-valent pneumococcal conjugate vaccine, administered concomitantly with influenza vaccine in healthy adults aged ...
  Randall Severance, Howard I Schwartz, Ron Dagan, Laurie Connor, Jianing Li, Alison Pedley, Jonathan Hartzel, Tina M. Sterling, Katrina M. Nolan, Gretchen M. Tamms, Luw...> ;Human Vaccines & Immunotherapeutics. 2021 Nov 2
• Further Considerations on the Natural History of Anal Dysplasia in Response to Jongen et al and Barroso L.
  Sandy H. Fang, Ulrike K. Buchwald> ;The Journal of Infectious Diseases. 2021 Oct 13
• 36 citations
  A phase 3 trial of safety, tolerability, and immunogenicity of V114, 15-valent pneumococcal conjugate vaccine, compared with 13-valent pneumococcal conjugate vaccine i...
  Heather L. Platt, Jose F. Cardona, Miwa Haranaka, Howard I. Schwartz, Silvia Narejos Perez, Anthony Dowell, Chih-Jen Chang, Ron Dagan, Gretchen M. Tamms, Tina M. Sterl...> ;Vaccine. 2021 Sep 7
• 21 citations
  Safety, tolerability, and immunogenicity of V114, a 15-valent pneumococcal conjugate vaccine, followed by sequential PPSV23 vaccination in healthy adults aged ≥50 year...
  Joon-Young Song, Chih-Jen Chang, Charles P. Andrews, Javier Díez-Domingo, Myoung Don Oh, Ron Dagan, Jonathan Hartzel, Alison Pedley, Jianing Li, Tina M. Sterling, Gret...> ;Vaccine. 2021 Sep 4
• 8 citations
  Sequential administration of Prevnar 13™ and PNEUMOVAX™ 23 in healthy participants 50 years of age and older.
  Ulrike K. Buchwald, Charles P. Andrews, John Ervin, James T. Peterson, Gretchen M. Tamms, David Krupa, Patrick Ajiboye, Lucy Roalfe, Andrea Likos Krick, Tina M. Sterli...> ;Human Vaccines & Immunotherapeutics. 2021 May 21
• 9 citations
  Immunogenicity following revaccination or sequential vaccination with 23-valent pneumococcal polysaccharide vaccine (PPSV23) in older adults and those at increased ris...
  Allan W. Cripps, Temitope Folaranmi, Kelly D Johnson, Luwy Musey, Michael S. Niederman, Ulrike K. Buchwald> ;Expert Review of Vaccines. 2021 Mar 2
• 25 citations
  Efficacy and effectiveness of a 23-valent polysaccharide vaccine against invasive and noninvasive pneumococcal disease and related outcomes: a review of available evid...
  Michael S. Niederman, Temitope Folaranmi, Ulrike K. Buchwald, Luwy Musey, Allan W. Cripps, Kelly D Johnson> ;Expert Review of Vaccines. 2021 Feb 20
• Join now to see all